Fetroja: which tox species, and why?

“The clinical formulation of cefiderocol, was tested in the repeat-dose toxicology studies described below. Rats and monkeys were the primary rodent and nonrodent species used in toxicology testing of this drug product.”

“In the response, the Applicant explained that in exploratory single-dose studies in dog, vomiting was observed several times from during dosing to 1 hour after the end of dosing at 1000 mg/kg, reason for which the Applicant considered that dogs would not tolerate repeat-dosing at the 1000 mg/kg dose level.”

“The clinical formulation of cefiderocol, was tested in the repeat-dose toxicology studies described below.”

“The clinical formulation of cefiderocol, was tested in the repeat-dose toxicology studies described below. Rats and monkeys were the primary rodent and nonrodent species used in toxicology testing of this drug product.”

“Developmental toxicity was not observed in rats at intravenous doses of up to 1000 mg/kg/day or mice at subcutaneous doses of up to 2000 mg/kg/day given during the period of organogenesis (gestation days 6-17 in rats and 6-15 in mice).”

“Carcinogenicity studies were not conducted. CHMP agreed that carcinogenicity studies were not needed as the SmPC states that the duration of dosing will be generally 14 days or less (not exceeding 21 days).”

“The clinical formulation of cefiderocol, was tested in the repeat-dose toxicology studies described below.”